Medical Developments International Ltd (MVP)
Australian Securities Exchange · Australia · prices in AUD · close of 19 Oct 2026
Key indicators
| Last close | AUD 0.405 |
|---|---|
| 52-week range | 0.365 – 0.745 |
| Return, 1 month / 3 months | −15.6% / +8.0% |
| Return, 1 year / 3 years | −43.0% / −51.2% |
| Trend | Below its 200-day average |
| RSI (14) | 38 |
| Volatility (1 year) | 67.4% |
| Worst drawdown (1 year) | -50.3% |
| Average daily value traded | 0.08M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Medical Developments International is an Australian healthcare company based in Melbourne. It makes the Penthrox inhaler, a hand-held device that delivers a pain-relieving vapour for emergency and procedural use, and it supplies related medical equipment. The company also develops and sells respiratory products, including spacers and devices used in asthma care, serving hospitals, ambulance services, clinics and other healthcare customers in Australia and overseas markets.
The shares are listed on the Australian Securities Exchange in Australia under the code MVP, and the price on this page is in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Medical Developments International Ltd (MVP) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.405 on 19 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 656 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 43.0% and over the last three months it rose 8.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -7.9% | ||
| From 52-week high | -45.6% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 8.0% | ||
| 6-month return | 5.2% | ||
| 12-month return, skipping the last month | -32.4% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 67.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -50.3% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.08M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −5.8% |
|---|---|
| 1 month | −15.6% |
| 3 months | +8.0% |
| 6 months | +5.2% |
| 1 year | −43.0% |
| 3 years | −51.2% |
| 5 years | −91.3% |
Signals
| 50-day / 200-day average | 0.460 / 0.440 |
|---|---|
| Golden / death cross (60 days) | Golden, 29 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.019 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 Mar 2020 | AUD 0.0192 |
| 3 Sep 2019 | AUD 0.0192 |
| 7 Mar 2019 | AUD 0.0192 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.